Shandong Shanda Wit Science and Technology Co Ltd (000915) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Shanda Wit Science and Technology Co Ltd (000915) has a cash flow conversion efficiency ratio of 0.152x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥620.45 Million ≈ $90.79 Million USD) by net assets (CN¥4.08 Billion ≈ $596.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shandong Shanda Wit Science and Technology Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Shandong Shanda Wit Science and Technology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 000915 current and long-term liabilities for a breakdown of total debt and financial obligations.
Shandong Shanda Wit Science and Technology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Shanda Wit Science and Technology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Everlight Electronics Co Ltd
TW:2393
|
0.030x |
|
Star Petroleum Refining Co Ltd
BK:SPRC
|
-0.073x |
|
CBL & Associates Properties Inc
NYSE:CBL
|
0.204x |
|
Soulbrain Holdings Co. Ltd
KQ:036830
|
0.005x |
|
Banco Patagonia
BA:BPAT
|
-0.006x |
|
Graincorp Ltd
AU:GNC
|
0.239x |
|
Tianshui Zhongxing Bio-technology Co Ltd
SHE:002772
|
0.042x |
|
Nitratos de Chile SA
SN:NITRATOS
|
0.085x |
Annual Cash Flow Conversion Efficiency for Shandong Shanda Wit Science and Technology Co Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Shanda Wit Science and Technology Co Ltd from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Shandong Shanda Wit Science and Technolo.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.41 Billion ≈ $645.68 Million |
CN¥929.61 Million ≈ $136.03 Million |
0.211x | -19.35% |
| 2023-12-31 | CN¥4.50 Billion ≈ $658.00 Million |
CN¥1.17 Billion ≈ $171.89 Million |
0.261x | -11.32% |
| 2022-12-31 | CN¥4.06 Billion ≈ $594.32 Million |
CN¥1.20 Billion ≈ $175.07 Million |
0.295x | +32.48% |
| 2021-12-31 | CN¥3.40 Billion ≈ $497.44 Million |
CN¥755.85 Million ≈ $110.61 Million |
0.222x | -11.27% |
| 2020-12-31 | CN¥2.94 Billion ≈ $429.52 Million |
CN¥735.55 Million ≈ $107.63 Million |
0.251x | +164.15% |
| 2019-12-31 | CN¥2.57 Billion ≈ $375.65 Million |
CN¥243.54 Million ≈ $35.64 Million |
0.095x | -58.77% |
| 2018-12-31 | CN¥2.34 Billion ≈ $342.53 Million |
CN¥538.56 Million ≈ $78.81 Million |
0.230x | +19.80% |
| 2017-12-31 | CN¥2.22 Billion ≈ $324.66 Million |
CN¥426.11 Million ≈ $62.35 Million |
0.192x | -25.26% |
| 2016-12-31 | CN¥1.95 Billion ≈ $285.25 Million |
CN¥500.91 Million ≈ $73.30 Million |
0.257x | +48.70% |
| 2015-12-31 | CN¥1.68 Billion ≈ $245.77 Million |
CN¥290.24 Million ≈ $42.47 Million |
0.173x | -5.97% |
| 2014-12-31 | CN¥1.48 Billion ≈ $216.90 Million |
CN¥272.41 Million ≈ $39.86 Million |
0.184x | -1.32% |
| 2013-12-31 | CN¥1.16 Billion ≈ $169.76 Million |
CN¥216.05 Million ≈ $31.62 Million |
0.186x | +7.77% |
| 2012-12-31 | CN¥946.05 Million ≈ $138.44 Million |
CN¥163.48 Million ≈ $23.92 Million |
0.173x | -4.43% |
| 2011-12-31 | CN¥769.24 Million ≈ $112.56 Million |
CN¥139.09 Million ≈ $20.35 Million |
0.181x | -38.03% |
| 2010-12-31 | CN¥649.52 Million ≈ $95.05 Million |
CN¥189.51 Million ≈ $27.73 Million |
0.292x | +18.77% |
| 2009-12-31 | CN¥526.71 Million ≈ $77.07 Million |
CN¥129.39 Million ≈ $18.93 Million |
0.246x | +16.04% |
| 2008-12-31 | CN¥443.06 Million ≈ $64.83 Million |
CN¥93.80 Million ≈ $13.73 Million |
0.212x | -17.66% |
| 2007-12-31 | CN¥393.55 Million ≈ $57.59 Million |
CN¥101.20 Million ≈ $14.81 Million |
0.257x | +79.88% |
| 2006-12-31 | CN¥363.40 Million ≈ $53.18 Million |
CN¥51.95 Million ≈ $7.60 Million |
0.143x | -22.52% |
| 2005-12-31 | CN¥343.51 Million ≈ $50.27 Million |
CN¥63.38 Million ≈ $9.27 Million |
0.184x | +87.65% |
| 2004-12-31 | CN¥310.43 Million ≈ $45.43 Million |
CN¥30.52 Million ≈ $4.47 Million |
0.098x | +1111.11% |
| 2003-12-31 | CN¥299.64 Million ≈ $43.85 Million |
CN¥2.43 Million ≈ $355.95K |
0.008x | +112.45% |
| 2002-12-31 | CN¥253.39 Million ≈ $37.08 Million |
CN¥-16.53 Million ≈ $-2.42 Million |
-0.065x | -11925.11% |
| 2001-12-31 | CN¥245.49 Million ≈ $35.92 Million |
CN¥-133.16K ≈ $-19.49K |
-0.001x | +99.84% |
| 2000-12-31 | CN¥258.69 Million ≈ $37.85 Million |
CN¥-90.48 Million ≈ $-13.24 Million |
-0.350x | -303.55% |
| 1999-12-31 | CN¥262.99 Million ≈ $38.48 Million |
CN¥45.19 Million ≈ $6.61 Million |
0.172x | -12.93% |
| 1998-12-31 | CN¥122.61 Million ≈ $17.94 Million |
CN¥24.20 Million ≈ $3.54 Million |
0.197x | -- |
About Shandong Shanda Wit Science and Technology Co Ltd
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration s… Read more